---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-178604"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T15:04:03.095951+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics annual meeting: Garren elected director, auditor ratified

## Summary
- Hideki Garren elected Class I director with 3,414,906 for, 405,471 withheld, 221,601 broker non-votes.
- Ratification of Weaver & Tidwell as independent auditor received 4,008,651 for, 31,504 against, 1,823 abstain.
- All proposals passed at the June 28, 2023 annual meeting.

## SEC filing metadata
- accession: 0001193125-23-178604
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312523178604/0001193125-23-178604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312523178604/d531146d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-178604
- JSON: https://secwatch.observer/filing/0001193125-23-178604.json
- Plain text: https://secwatch.observer/filing/0001193125-23-178604.txt

## Key facts
- Shareholder Votes
  Coya Therapeutics, Inc. shareholders approved Ratification of appointment of Weaver and Tidwell, L.L.P. as independent registered public accounting firm at the 2023-06-28 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-28
  source text: The proposal to ratify the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for our fiscal year ending December 31, 2023 was approved based upon the following votes: For Against Abstain 4,008,651 31,504 1,823
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312523178604/0001193125-23-178604-index.htm
- Shareholder Votes
  Coya Therapeutics, Inc. shareholders approved Election of Hideki Garren, M.D., Ph.D. as a Class I director at the 2023-06-28 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-28
  source text: The election of Hideki Garren, M.D., Ph.D. as a Class I director to hold office for a term of three years, until his successor is duly elected and qualified or he is otherwise unable to complete his term. The votes were cast for this matter were as follows: Nominee For Withheld Broker Non-Votes Hideki Garren, M.D., Ph.D. 3,414,906 405,471 221,601
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312523178604/0001193125-23-178604-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.